Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Renal Cell Cancer – Triplet Therapy Improves Outcomes

Background

A significant period until disease progression was seen in patients with metastatic renal cell cancer (RCC) receiving the triplet combination of Cometriq plus Yervoy and Opdivo, according to a study presented at the annual meeting of the European Society for Medical Oncology, held Sept. 9 to 13 in Paris.

The name of the study is “COSMIC-313”.

About the Study

The COSMIC-313 phase 3 trial compared the modern active control of doublet therapy (Opdivo plus Yervoy) to triplet therapy (Cometriq plus Yervoy and Opdivo) for first-line treatment of metastatic RCC.

855 previously untreated renal cell cancer patients were randomly assigned to Cometriq (40 mg daily; 428 patients) or placebo (427 patients).

All patients received Opdivo (3 mg/kg every three weeks) plus Yervoy (1 mg/kg every three weeks) for four cycles followed by Opdivo (480 mg every four weeks for up to two years).

Study Outcomes

The international group of researchers found that the primary endpoint which was the period until disease progression was achieved in the triplet therapy group:

The was a reduction of 27% in the risk of disease progression or death in the triplet group.

43 percent of patients experienced a shrinkage in tumor size for those receiving triplet therapy versus 36 percent for those receiving doublet therapy.

Median period until disease progression was not yet reached for patients receiving triplet therapy but was 11.3 months for patients receiving doublet therapy.

Side Effects

As might be anticipated with treatment intensification, side effects were higher with the triplet combination. No new safety signals were identified for any of the components.

Nearly three-fourths of patients receiving triplet therapy experienced harsh side effects versus 41 percent with doublet therapy.

Discontinuation of all treatment components due to treatment-related side effects occurred in 12 percent of patients receiving triplet therapy versus 5 percent receiving doublet therapy.

Conclusion

We must see next how to integrate this regimen – Cometriq plus Yervoy and Opdivo – into practice as first line treatment in metastatic renal cancer, if approved by regulatory authorities.

Talk to us so see if we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

Read more about Renal cancer >>

Renal Cell Cancer - Triplet Therapy Improves Outcomes
Renal Cell Cancer – Triplet Therapy Improves Outcomes

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics